Please assess the completion status of the following clinical trial:

Trial Title: Analyze the Myelin-TRAP as Diagnostic Tool in Multiple Sclerosis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* These criteria depend on the subgroup belongs to the patient.~* Signed consent~* Membership of a social security system~Exclusion Criteria:~* Whatever the patient group or control:~* Processing immunosuppressive.~* Processing by a monoclonal antibody.~* Previous treatment with an immunosuppressant for a significant period of time (more than 6 months of oral treatment, more than 6 cycles of cyclophosphamide over 3 cures mitoxantrone).~* Carcinomatous pathology known evolving.~* People under guardianship.~* Pregnant women.~* Patients not motivated to study. Known patients with anemia (hemoglobin \<10g/100ml)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Relapsing Multiple Sclerosis- group 1 (Type: OTHER): Definite multiple sclerosis according to the McDonald criteria, relapsing Patient innocent of thorough treatment or treatment immunomodulator stopped for at least 6 months.
- Relapsing Multiple Sclerosis- group 2 (Type: OTHER): Multiple sclerosis defined according to the criteria of McDonald, relapsing Patient under treatment immunomodulator for at least 6 months.
- secondary progressive multiple sclerosis- Group 3 (Type: OTHER): Multiple sclerosis defined according to the criteria of McDonald, secondary progressive multiple sclerosis
- primary progressive multiple sclerosis- group 4 (Type: OTHER): Multiple sclerosis defined according to the criteria of McDonald, primary progressive multiple sclerosis
- control 1 (Type: OTHER): healthy volunteers
- Control 2 (Type: OTHER): Patients with central or peripheral neurological non-inflammatory, non-autoimmune.
- Control 3 (Type: OTHER): Patients having an autoimmune pathology

Based on this trial design, predict the completion outcome and termination type (if applicable).